Cas No. 214470-57-2, Methyl 4-(3-chloropropoxy)-5-Methoxy-2-nitrobenzoate

Bosutinib, a potent tyrosine kinase inhibitor, holds immense promise in the treatment of various cancers, including chronic myeloid leukemia (CML). Our intermediates are meticulously crafted to meet your production needs, ensuring the seamless synthesis of Bosutinib and enabling its widespread availability. Partner with us to make a lasting impact on cancer care, providing patients with a breakthrough therapy that could reshape their lives. Together, let's accelerate the development of Bosutinib and pave the way for improved cancer treatments.